Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 subcutaneous efgartigimod PH20 in adults with primary Sjögren's disease
MOH_2025-04-27_014053Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Apr 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efgartigimod alfa in Sjögren's syndrome (3 arms), sponsored by argenx. Primary endpoint: Efficacy. Started Apr 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2025-04-27_014053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-27_014053.